<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04807842</url>
  </required_header>
  <id_info>
    <org_study_id>MGAP BV 001</org_study_id>
    <nct_id>NCT04807842</nct_id>
  </id_info>
  <brief_title>Multi-Gyn ActiGel Plus for Treatment of Bacterial Vaginosis</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled Study to Confirm the Efficacy and Safety of Multi- Gyn ActiGel Plus for Treatment of Bacterial Vaginosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioClin BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Avania</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Karo Pharma AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled clinical investigation. The objective&#xD;
      of the study is to confirm the efficacy of Multi-Gyn ActiGel Plus to treat BV as compared to&#xD;
      a placebo control.&#xD;
&#xD;
      Treatment arm 1: Multi-Gyn ActiGel Plus Treatment arm 2: placebo gel Both the Multi-Gyn&#xD;
      ActiGel Plus and the placebo will be applied twice a day for 7 consecutive days. Visit 2 will&#xD;
      be performed at 3 weeks after start of treatment A phone call will take place, at 5 weeks&#xD;
      after start of treatment for subject with clinical cure at Visit 2. The total duration per&#xD;
      subject is estimated 5 weeks and the total study duration is 13 months. Sample size is 100&#xD;
      subjects per treatment arm.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double blinded, randomized placebo controlled.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical cure rate of BV at 3 weeks after start of treatment (end-of treatment visit; Visit 2).</measure>
    <time_frame>3 weeks</time_frame>
    <description>Clinical cure is defined based on the following Amsel criteria:&#xD;
presence of clue cells &lt;20% of the total epithelial cells on microscopic examination of the saline wet mount&#xD;
resolution of the abnormal vaginal discharge, and&#xD;
a negative whiff test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiological cure rate (based on Nugent score &lt;4) at Visit 2</measure>
    <time_frame>3 weeks</time_frame>
    <description>The secondary objective of the study is to confirm the secondary efficacy of the product.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Bacterial Vaginoses</condition>
  <arm_group>
    <arm_group_label>Active product</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>vaginal gel</intervention_name>
    <description>The placebo gel is a non-buffered gel. The active device is an acidic gel.</description>
    <arm_group_label>Active product</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women diagnosed with BV (3 out of 4 Amsel criteria positive, with at least presence of&#xD;
             clue cells (&gt;20%))&#xD;
&#xD;
          -  Women of childbearing potential&#xD;
&#xD;
          -  Aged &gt;18 years&#xD;
&#xD;
          -  Signed written informed consent form&#xD;
&#xD;
          -  Willing to comply to the follow-up schedule&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current clinically manifest of sexually transmitted gynecologically infection, genital&#xD;
             tract infection, vulvovaginal candidosis or aerobic vaginitis (incl. clinical obvious&#xD;
             gonorrhoea, chlamydia trachomatis or mycoplasma genitalium infection with cervicitis,&#xD;
             urethritis, salpingitis)&#xD;
&#xD;
          -  Presence of Trichomonas and/or Candida Albicans in vaginal smear during examination of&#xD;
             the smears for Amstel criteria (clue cells detection)&#xD;
&#xD;
          -  Current genital malignancies&#xD;
&#xD;
          -  Chemotherapy for any reason in last 6 months&#xD;
&#xD;
          -  Radiotherapy in the genitourinary system in the last 12 months&#xD;
&#xD;
          -  Use of antibiotics for any reason in the last 14 days&#xD;
&#xD;
          -  Use of intrauterine or intravaginal devices during the investigation or in the last 14&#xD;
             days&#xD;
&#xD;
          -  Pregnancy or currently attempting to conceive&#xD;
&#xD;
          -  Lactation&#xD;
&#xD;
          -  Use of other treatment for vaginal conditions during the course of the clinical&#xD;
             investigation&#xD;
&#xD;
          -  Known allergies to ingredients of the product&#xD;
&#xD;
          -  Concomitant medication for treatment of vaginal infections, or other use of&#xD;
             intravaginal medication during the course of the clinical investigation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Diana Zeneli, MD</last_name>
    <phone>0031614706949</phone>
    <email>diana.pasho@karopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Praxis Dr. Peters</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus H Peters, Dr.med</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 18, 2021</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginosis, Bacterial</mesh_term>
    <mesh_term>Vaginal Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

